Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LIPE | Q05469 | 4/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.39 |
| ▸ | IP6K3 | Q96PC2 | 2/20 | 0.39 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3220986 | 0.84 | RAB9A (0.58) | LMNASMN1; SMN2LIPEPPARGRAB9A | |
| SCHEMBL3209482 | 0.79 | LMNA (0.50) | MAPK1LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL3212757 | 0.78 | PPARG (0.58) | MAPK1LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL3210317 | 0.77 | PPARG (0.55) | MAPK1LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL5647172 | 0.73 | MAPK1 (1.00) | MAPK1LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL37462 | 0.72 | ALDH1A1 (0.63) | TSHRERN1TDP1TRIM24TYR | |
| SCHEMBL10854830 | 0.72 | MAPK1 (0.97) | MAPK1LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL9711425 | 0.71 | MAPK1 (0.77) | MAPK1LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL2476407 | 0.71 | LMNA (0.67) | MAPK1LMNACYP2C9TSHRAPEX1 | |
| SCHEMBL30434705 | 0.71 | MAPK1 (0.58) | MAPK1LMNACYP2C9TSHRAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| EP-1912645-A2 | THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
| WO-2007018314-A2 | THERAPEUTIC AGENT FOR DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | MAPK1 851/4885LMNA 1909/4885CYP2C9 4125/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | MAPK1 932/4885LMNA 2486/4885CYP2C9 4091/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | MAPK1 851/4885LMNA 1909/4885CYP2C9 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.